Paclitaxel poliglumex

Summary

Paclitaxel poliglumex (CT-2103, Xyotax) is a biodegradable polymeric drug conjugate of paclitaxel and poly-L-glutamic acid developed to improve the pharmacokinetic profile and tolerability of paclitaxel, reduce systemic toxicity, and enhance tumor targeting via the EPR effect. It completed Phase III clinical trials for non-small cell lung cancer (NSCLC) and ovarian cancer but did not receive FDA approval based on pivotal trial results. It demonstrated some evidence of preferential activity in women with higher estrogen levels.

Mechanism of Action

Paclitaxel poliglumex is a macromolecular drug conjugate in which paclitaxel is covalently linked to poly-L-glutamic acid via an ester bond. The polyglutamate carrier enables passive tumor targeting through the enhanced permeability and retention (EPR) effect. Once internalized, lysosomal proteases cleave the glutamic acid backbone, releasing free paclitaxel, which stabilizes microtubules by binding to beta-tubulin, inhibiting depolymerization and thereby arresting cell division at the G2/M phase, leading to apoptosis.

Routes of Administration

Goals & Uses

• Ovarian cancer treatmentOncologyModerate
• Non-small cell lung cancer treatmentOncologyModerate
• Reduced hypersensitivity vs. solvent-based paclitaxelTolerability ImprovementModerate
• Improved therapeutic index via tumor targetingDrug DeliveryLow

Contraindications

• Severe hepatic impairmentOrganModerateLiver function concerns
• Severe hypersensitivity to paclitaxel or polyglutamate componentsAllergyHigh
• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• Severe baseline neuropathyNeurologicalModerate

Adverse Effects

• Peripheral neuropathyNeurologicalCommon
• Hypersensitivity reactionsImmunologicUncommon
• AlopeciaDermatologicCommonHair loss
• Nausea and vomitingGastrointestinalCommon
• NeutropeniaHematologicCommonLow neutrophil count
• FatigueGeneralCommonLow energy or tiredness

Drug Interactions

• CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)Moderate
• CYP2C8 inhibitors (e.g., gemfibrozil)Moderate
• Other myelosuppressive agentsHigh

Population Constraints

• Patients with pre-existing severe peripheral neuropathyNeurologicalRelative
• Pediatric patientsAgeRelative
• Pregnant womenReproductiveAbsolute
• Severe hepatic impairmentOrgan ImpairmentRelative

Regulatory Status

• European UnionUnapprovedNo marketing authorization granted by EMA; development discontinued.
• United StatesUnapprovedNDA submitted in 2005 for first-line NSCLC; FDA issued Complete Response Letter citing lack of demonstrated superior efficacy. Not approved.
• United KingdomUnapprovedNever received MHRA approval; not commercially available.

FDA issued a Complete Response Letter in 2005 following NDA submission for first-line NSCLC treatment; approval was not granted due to insufficient evidence of superior efficacy over standard paclitaxel. The compound has not been approved by FDA, EMA, or other major regulatory agencies. Development has been largely discontinued for the original indications.

Evidence & Sources

No sources recorded yet.